For those with Multiple Sclerosis: Acorda Therapeutics Announces FDA Acceptance of Fampridine-SR New Drug Application for Filing
Posted Nov 17 2009 10:20pm
FDA Assigns Priority Review and PDUFA Date of October 22, 2009 No Current Therapies Indicated to Improve Walking Ability in People with MS
HAWTHORNE, N.Y. --(BUSINESS WIRE)-- May. 6, 2009--Acorda Therapeutics, Inc. (Nasdaq: ACOR ) today announced that the U.S. Food and Drug Administration ( FDA ) has accepted the Fampridine-SR New Drug Application (NDA) for filing, assigning Priority Review and a Prescription Drug User Fee Act (PDUFA) date of October 22, 2009. The PDUFA date is the target date for the FDA to complete its review of the Fampridine-SR NDA.
“I am pleased that we were able to work quickly to address the comments from the FDA and resubmit our NDA approximately three weeks from having received the Refuse to File letter on our initial NDA submission, and that the FDA accepted the filing less than two weeks later,” said Ron Cohen, M.D., Acorda Therapeutics’ President and CEO. “We are also encouraged that the FDA has elected to assign Priority Review status to the Fampridine-SR NDA.”
Fampridine-SR is a sustained-release tablet formulation of the investigational drug fampridine (4-aminopyridine or 4-AP). In laboratory studies, fampridine has been found to improve impulse conduction in nerve fibers in which the insulating layer, called myelin, has been damaged. Fampridine-SR is being developed by Acorda Therapeutics and manufactured by Elan Corporation plc.
. Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You ============================================